Form D · Biotechnology
Origin Endoscopy Inc.
Englewood, CO · CIK 0002039132
Offering snapshot reported Jun 10, 2025 · SEC filing
- Reported sold
- $2.34M Offering amount: $2.64M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Sep 18, 2024 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$1,590,329 → $2,340,326
- Reported investors3 → 5
- Minimum accepted$150,000 → $10,000
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2025 | Amendment | $2,340,326 | $749,997vs Oct 3, 2024 | 5 | SEC filing |
| Oct 3, 2024 | Amendment | $1,590,329 | $640,329vs Sep 27, 2024 | 3 | SEC filing |
| Sep 27, 2024 | Initial | $950,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-525306
Source: Form D, filed Jun 10, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Freeman | Director |
| Jason Grimes | Director |
| Stephen Hoag | Director |
| Jeremy Starkweather | Director, Executive |
| John Wynne | Director, Executive |
| Jason Ylizarde | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9800 Pyramid Ct Suite 400
Englewood, CO, 80112
Englewood, CO, 80112